Carl R Alving

List of Publications by Year
in descending order

43 papers	1,986 citations	257450 24 h-index	265206 42 g-index
44 all docs	44 docs citations	44 times ranked	1866 citing authors

#	Article	IF	Citations
1	Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating APOBEC3A. Scientific Reports, 2022, 12, 7570.	3.3	3
2	Liposome Formulations as Adjuvants for Vaccines. Current Topics in Microbiology and Immunology, 2021, 433, 1-28.	1.1	9
3	Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and Society. Military Medicine, 2021, 186, 72-77.	0.8	4
4	Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. Vaccines, 2021, 9, 272.	4.4	16
5	Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. Npj Vaccines, 2021, 6, 148.	6.0	14
6	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathogens, 2020, 16, e1008764.	4.7	37
7	Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Review of Vaccines, 2020, 19, 279-292.	4.4	59
8	Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine, 2019, 37, 3793-3803.	3.8	39
9	Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge. Vaccine, 2019, 37, 516-523.	3.8	4
10	Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. Journal of Liposome Research, 2019, 29, 247-250.	3.3	8
11	Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. Journal of Controlled Release, 2018, 275, 12-19.	9.9	39
12	Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. Vaccine, 2017, 35, 5448-5454.	3.8	49
13	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. Npj Vaccines, 2017, 2, 13.	6.0	34
14	Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine, 2017, 35, 3865-3874.	3.8	58
15	Liposomal adjuvants for human vaccines. Expert Opinion on Drug Delivery, 2016, 13, 807-816.	5.0	85
16	Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM₁₉₇ Carriers. Bioconjugate Chemistry, 2015, 26, 1041-1053.	3.6	61
17	Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine, 2015, 33, 5578-5587.	3.8	60
18	Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 775-780.	2.6	48

#	Article	IF	Citations
19	Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine, 2013, 31, 2804-2810.	3.8	69
20	Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Review of Vaccines, 2012, 11, 733-744.	4.4	107
21	Oil-in-Water Liposomal Emulsions for Vaccine Delivery. Methods in Enzymology, 2003, 373, 34-50.	1.0	33
22	Design and selection of vaccine adjuvants: animal models and human trials. Vaccine, 2002, 20, S56-S64.	3.8	108
23	Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nature Medicine, 2000, 6, 1403-1406.	30.7	327
24	The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (DoxilÂ®). Journal of Liposome Research, 2000, 10, 467-481.	3.3	75
25	Advances in vaccine delivery: transcutaneous immunisation. Expert Opinion on Investigational Drugs, 1999, 8, 797-805.	4.1	46
26	Complement-Mediated Acute Effects of Liposome-Encapsulated Hemoglobin. Artificial Cells, Blood Substitutes, and Biotechnology, 1999, 27, 23-41.	0.9	18
27	Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine, 1999, 17, S37-S43.	3.8	43
28	Commentary: Some Thoughts on an International Liposome Society. Journal of Liposome Research, 1999, 9, ix-xii.	3.3	0
29	Skin immunization made possible by cholera toxin. Nature, 1998, 391, 851-852.	27.8	250
30	Emulsification of Liposomes with Incomplete Freund's Adjuvant: Stability of the Liposomes and the Emulsion. Journal of Liposome Research, 1998, 8, 183-194.	3.3	5
31	Toxic effects of antileishmanial reverse-phase evaporation liposomes containing dicetyl phosphate in monkeys. Drug Delivery, 1995, 2, 181-189.	5.7	5
32	Complement Activation by Liposome-Encapsulated HemoglobinIn Vitro: The Role of Endotoxin Contamination. Artificial Cells, Blood Substitutes, and Biotechnology, 1995, 23, 355-363.	0.9	19
33	Prospects for an Anticholesterol Vaccine. BioDrugs, 1995, 3, 409-414.	0.7	6
34	Complement-Dependent Phagocytosis of Liposomes: Suppression by â€œStealthâ€•Lipids. Journal of Liposome Research, 1992, 2, 383-395.	3.3	25
35	Polymeric biodegradable liposphereså„¢ as vaccine delivery systems. Polymers for Advanced Technologies, 1992, 3, 351-357.	3.2	13
36	Studies on the Topography of the Catalytic Site of Acetylcholinesterase Using Polyclonal and Monoclonal Antibodies. Journal of Neurochemistry, 1990, 55, 756-763.	3.9	24

#	Article	IF	Citations
37	Naturally occurring autoantibodies to cholesterol in humans. Biochemical Society Transactions, 1989, 17, 637-639.	3.4	35
38	Life-Long Administration of Liposomes and Lipid A in Mice: Effects on Longevity, Antibodies to Liposomes, and Terminal Histopathological Patterns. Journal of Liposome Research, 1988, 1, 93-110.	3.3	13
39	Liposomes as carriers for a human malaria sporozoite vaccine. Biochemical Society Transactions, 1988, 16, 921-922.	3.4	6
40	Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Annals of Tropical Medicine and Parasitology, 1984, 78, 279-286.	1.6	29
41	Natural antibodies against phospholipids and liposomes in humans. Biochemical Society Transactions, 1984, 12, 342-343.	3.4	50
42	Immune Reactivities of Antibodies against Glycolipids. ACS Symposium Series, 1980, , 461-473.	0.5	14
43	LIGHT-INDUCED LEAKAGE OF SPIN LABEL MARKER FROM LIPOSOMES IN THE PRESENCE OF PHOTOTOXIC PHENOTHIAZINES. Photochemistry and Photobiology, 1976, 24, 41-48.	2.5	39